We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
BMS signs large-molecule licensing agreement with Ambrx
28 Aug 2019
Executive Summary
Ambrx Inc. (protein therapeutics and antibody-drug conjugates) has licensed Bristol-Myers Squibb Co. exclusive global rights to research, develop, and market modified forms of fibroblast growth Factor 21 (FGF-21) for Type II diabetes, and relaxin for heart failure, both currently in preclinical. NOTE: The FGF-21 therapeutic, also known as BMS986036, is also being tested in liver fat, liver injury, and fibrosis in nonalcoholic steatohepatitis patients.
Deal Industry
Pharmaceuticals
Biotechnology
Large Molecule
Synthesis Technologies, Production Processes
Deal Status
Final
Deal Type
Alliance
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?